• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    2/14/23 4:02:56 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRMY alert in real time by email
    SC 13G/A 1 tm235913d3_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

         

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    Harmony Biosciences Holdings, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    413197104

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

    *       The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      1. Name of Reporting Persons:
    HBM Healthcare Investments (Cayman) Ltd.
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) ¨
      3. SEC Use Only
      4. Citizenship or Place of Organization:
    Cayman Islands, British West Indies
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power:
    2,147,943
     
    6. Shared Voting Power:
    0
     
    7. Sole Dispositive Power:
    2,147,943
     
    8. Shared Dispositive Power:
    0
      9. Aggregate Amount Beneficially Owned by Each Reporting Person:
    2,147,943
     
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11. Percent of Class Represented by Amount in Row (9):
    3.6% (1)
     
      12. Type of Reporting Person (See Instructions):
    CO

     

    (1)        Based on 59,317,554 shares of Common Stock outstanding as of October 28, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 1, 2022.

     

     

     

     

    Item 1. (a). Name of Issuer:
    Harmony Biosciences Holdings, Inc.
      (b).

    Address of Issuer’s Principal Executive Offices:

    630 W. Germantown Pike

    Plymouth Meeting, PA 19462

     
    Item 2(a).  

    Name of Person Filing:

    HBM Healthcare Investments (Cayman) Ltd.

    Item 2(b).  

    Address of Principal Business Office:

    Governors Square

    23 Lime Tree Bay Avenue

    PO Box 30852

    Grand Cayman, Cayman Islands

    Item 2(c).  

    Citizenship:

     

    Cayman Islands, British West Indies

     

     

    Item 2(d).   Title of Class of Securities:
    Common Stock, par value $0.00001

     

    Item 2(e).   CUSIP Number:
    413197104
     
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       
      Not Applicable.
       
    Item 4. Ownership.
       
      (a)

    Amount beneficially owned:

     

    2,147,943 (1)

     

      (b)

    Percent of class:

     

    3.6% (2)

     

      (c)

    Number of shares as to which the Reporting Person has:

     

        (i)

    Sole power to vote or to direct the vote:

     

    2,147,943

     

        (ii)

    Shared power to vote or to direct the vote:

     

    0

     

        (iii)

    Sole power to dispose or to direct the disposition of:

     

    2,147,943

     

        (iv)

    Shared power to dispose or to direct the disposition of:

     

    0

     

     

     

     

     

    Item 5.

    Ownership of Five Percent or Less of a Class

       
      As of December 31, 2022, the Reporting Person ceased to be the beneficial owner of more than five percentage of the shares of Issuer’s Common Stock.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable.
       
    Item 10. Certification.
       
    Not Applicable.
       
     

    (1) 

    Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. (the “Board”). The Board consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. 

       
      (2)

    Based on 59,317,554 shares of Common Stock outstanding as of October 28, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 1, 2022.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

    HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD. 

         
      By: /s/ Jean-Marc LeSieur
      Name: Jean-Marc LeSieur
      Title: Managing Director

     

    SIGNATURE PAGE TO SCHEDULE 13G AMENDMENT NO. 2 (HARMONY BIOSCIENCES HOLDINGS, INC.)

     

     

     

    Get the next $HRMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRMY

    DatePrice TargetRatingAnalyst
    2/23/2026Buy → Hold
    Deutsche Bank
    2/23/2026Buy → Hold
    Truist
    2/11/2026$46.00Neutral
    UBS
    7/21/2025$48.00Buy
    Truist
    7/10/2025$33.00Neutral
    Goldman
    6/2/2025$61.00Outperform
    Oppenheimer
    2/11/2025$55.00Buy
    Deutsche Bank
    12/17/2024$75.00Buy
    H.C. Wainwright
    More analyst ratings

    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Harmony Biosciences downgraded by Deutsche Bank

    Deutsche Bank downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:47 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences downgraded by Truist

    Truist downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:36 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Harmony Biosciences with a new price target

    UBS resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $46.00

    2/11/26 7:39:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Mollichella Stephen M. claimed ownership of 2,506 shares (SEC Form 3)

    3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    7/22/26 4:04:00 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Germano Geno J

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    5/18/26 9:51:38 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Germano Geno J

    3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    5/18/26 9:50:42 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

    PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybi

    7/21/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

    WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentu

    7/16/26 8:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

    Agreement highlights Paragon's ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology companies that deliver important treatments to the patients who need them. Emalex is another Paragon Biosciences-founded company built to develop a novel class of treatment for patients with central nervous system disorders, following in the footsteps of other successful Paragon companies such as Harmony Biosciences (NASDAQ:HRMY). Ecopipam, an investigati

    6/11/26 3:03:00 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    SEC Filings

    View All

    Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    7/16/26 8:35:13 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Harmony Biosciences Holdings Inc.

    144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    7/2/26 4:06:38 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Harmony Biosciences Holdings Inc.

    144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    6/30/26 4:04:46 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Leadership Updates

    Live Leadership Updates

    View All

    $HRMY
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

    COMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and privately held companies, guiding them through key growth inflection points. With his experience as a sell-side analyst, investor and biotech CFO, he brings

    4/14/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

    Appointments support Harmony's next phase of growth and long‑term value creation Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechn

    4/2/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

    4/3/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

    PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybi

    7/21/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

    WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management Advancing with Pitolisant GR on Track for NDA Filing 2Q26, Pitolisant HD Phase 3 Data in 2027, and Recently Acquired Novel Amorphous Form of Pitolisant to Pursue Broader CNS Indications Potential Best-in-Class Orexin-2 Agonist with BP-205; Phase 1 Clinical PK Data On Track for Mid-2026 Renewed Focus on Business Development Opportunities with Emphasis on Revenue Potential in the 2028 to 2032 Timefra

    5/7/26 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien

    4/23/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 7:06:51 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 5:06:22 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/9/24 9:03:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care